Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Long-Term Debt Repayments (2021 - 2024)

Standard Biotools (LAB) has disclosed Long-Term Debt Repayments for 6 consecutive years, with $55.0 million as the latest value for Q4 2024.

  • On a quarterly basis, Long-Term Debt Repayments rose 4300.0% to $55.0 million in Q4 2024 year-over-year; TTM through Sep 2025 was $55.0 million, a 482.5% increase, with the full-year FY2024 number at $63.2 million, up 2933.7% from a year prior.
  • Long-Term Debt Repayments was $55.0 million for Q4 2024 at Standard Biotools, up from $8.2 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $55.0 million in Q4 2024 to a low of -$501000.0 in Q4 2021.
  • A 4-year average of $10.3 million and a median of $1.2 million in 2023 define the central range for Long-Term Debt Repayments.
  • Peak YoY movement for Long-Term Debt Repayments: skyrocketed 1264.87% in 2022, then surged 4300.0% in 2024.
  • Standard Biotools' Long-Term Debt Repayments stood at -$501000.0 in 2021, then soared by 1464.87% to $6.8 million in 2022, then crashed by 81.72% to $1.2 million in 2023, then soared by 4300.0% to $55.0 million in 2024.
  • Per Business Quant, the three most recent readings for LAB's Long-Term Debt Repayments are $55.0 million (Q4 2024), $8.2 million (Q1 2024), and $1.2 million (Q4 2023).